Highlights
Cardiovascular magnetic resonance (CMR) utilizing extracellular volume (ECV) mapping has emerged as a robust tool for the longitudinal assessment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Untreated ATTR-CM patients exhibit a significant and progressive increase in amyloid burden, with 62% showing disease progression by two years.
